A 51-year-old man weighing 80 kg and measuring 160 cm in height is diagnosed with pulmonary embolism. He is started on warfarin and requires concomitant enoxaparin therapy until a therapeutic INR is achieved. His laboratory results are as follows:
Laboratory Parameter | Result | Reference Range |
Serum creatinine | 85 µmol/L | 44–115 µmol/L |
Creatinine clearance (CrCl) | 103 mL/min | 70–103 mL/min |
Which of the following enoxaparin regimens is most appropriate for this patient?
A. Enoxaparin 30 mg subcutaneously every 24 hours
B. Enoxaparin 40 mg subcutaneously every 24 hours
C. Enoxaparin 80 mg subcutaneously every 12 hours
D. Enoxaparin 160 mg subcutaneously every 12 hours
Correct Answer: C. Enoxaparin 80 mg subcutaneously every 12 hours
Rationale:
For acute treatment of pulmonary embolism (PE) or VTE (with or without concurrent warfarin bridging), the standard enoxaparin regimen is 1 mg/kg subcutaneously every 12 hours (preferred in most guidelines) or the alternative of 1.5 mg/kg once daily.
Patient weight = 80 kg → 1 mg/kg = 80 mg every 12 hours.
Creatinine clearance is normal (103 mL/min), so no renal dose adjustment is required. (Adjustment to 1 mg/kg once daily applies only when CrCl < 30 mL/min.)
Height/BMI (≈31) does not change the recommendation; actual body weight is used for therapeutic dosing in non-morbidly obese patients.
Why the other options are incorrect:
A (30 mg q24h) and B (40 mg q24h) are prophylactic doses used for VTE prevention in medical or surgical patients, not treatment of established PE.
D (160 mg q12h) is twice the recommended therapeutic dose (2 mg/kg q12h) and would significantly increase bleeding risk.
Enoxaparin is continued for a minimum of 5 days and until the INR is therapeutic (typically 2–3) for at least 24 hours when bridging to warfarin.
Exam pearl: Enoxaparin dosing differs by indication: prophylaxis commonly uses fixed doses, whereas treatment of acute PE generally requires weight-based therapeutic dosing.
A 65-year-old man presents to a pharmacy to refill his medications. Upon reviewing his refill history, the pharmacist notices that the patient does not refill his medications regularly. When questioned, the patient reports that he takes multiple medications with complex administration schedules.
Which of the following factors is most likely contributing to this patient's medication nonadherence?
A. Patient related factors
B. Provider related factors
C. Health care system factors
D. Medication and condition factor
The correct answer is D. Medication and condition factor.
Explanation:
The World Health Organization (WHO) categorizes factors influencing medication non-adherence into five dimensions:
➡Therapy- / Medication-related factors: Characteristics of the treatment regimen itself, such as complexity (e.g., polypharmacy, multiple daily doses), administration instructions, side effects, and duration of treatment.
➡Patient-related factors: Patient knowledge, beliefs, attitudes, motivation, cognitive impairment, or physical disabilities (e.g., visual or dexterity problems).
➡Health care team / Provider-related factors: Quality of doctor-patient communication, lack of follow-up, or inadequate education provided by healthcare staff.
➡Health care system factors: High cost of care, lack of drug access, long wait times, or inadequate insurance coverage.
➡Social and economic factors: Poverty, low health literacy, lack of social support, or family instability.
In this scenario, the patient states that the reason for non-adherence is having multiple medications that require complex administration. Regimen complexity and polypharmacy are classic therapy- or medication-related factors.
Why Other Options Are Incorrect:
A. Patient related factors: This category refers to the patient's internal attributes (e.g., health literacy, forgetfulness, fear of side effects, denial of illness).
B. Provider related factors: This relates to the clinician's communication skills, empathy, or failure to properly explain the regimen.
C. Health care system factors: This pertains to structural, insurance, cost, or access barriers within the healthcare system.
What is the best intervention for this patient:
The best intervention is to simplify the medication regimen and provide practical adherence support tools. Since the primary barrier is regimen complexity (multiple medications with complex administration), the most effective approach targets that barrier directly.
Recommended interventions (in priority order) 1. Pharmacist-led medication review / regimen simplification (most important) ★Conduct a comprehensive medication review (or Medication Therapy Management / CMR). ★Collaborate with the prescriber to: ✔Reduce the number of daily doses (switch to once-daily formulations where possible). ✔Use combination products to lower pill burden. ✔Deprescribe unnecessary or low-value medications. ✔Align administration times so medications can be taken together. This directly addresses the “complex administration” issue the patient reported. 2. Adherence packaging / compliance aids ★Multicompartment compliance aids (blister packs, weekly pill organizers, or pharmacy-prepared multi-dose packaging). ★These reduce the cognitive and physical burden of managing multiple bottles and complex schedules. 3. Medication synchronization (appointment-based model) ★Align all refill dates so the patient picks up everything on one day each month. ★Reduces the number of pharmacy visits and the chance of running out of individual medications. 4. Personalized education and counseling ★Use teach-back to confirm the patient understands the simplified schedule. ★Provide a clear, written medication list or calendar with administration times and any special instructions (e.g., with/without food). Why this approach works best: ★Evidence consistently shows that reducing regimen complexity (fewer daily doses, combination products, simplified schedules) and pharmacist-led interventions produce meaningful improvements in adherence, especially in older adults with polypharmacy. ★Packaging aids and refill synchronization provide additional practical support and are highly effective when complexity is the main barrier. ★Simply educating the patient without simplifying the regimen is usually insufficient. Which of the following medications for osteoporosis will significantly reduce the risk of hip fracture? A. Phosphate B. Risedronate C. Raloxifene D. Calcitonin
Explanation: Risedronate is a bisphosphonate with robust evidence from randomized controlled trials (including the HIP study) demonstrating a significant reduction in the risk of hip fractures (as well as vertebral and non-vertebral fractures) in postmenopausal women with osteoporosis.
Comparison with the other options:
A. Phosphate — Not a standard pharmacological treatment for osteoporosis and has no established role in reducing fracture risk. C. Raloxifene — A selective estrogen receptor modulator (SERM) that reduces vertebral fracture risk, but has not been shown to significantly reduce hip or other non-vertebral fractures. D. Calcitonin — Modestly reduces vertebral fracture risk but has no proven benefit for hip or non-vertebral fractures. Among the listed options, only Risedronate has demonstrated significant efficacy in reducing hip fracture risk.
Exam pearl: Bisphosphonates such as alendronate, risedronate, and zoledronic acid are important osteoporosis treatments that reduce hip-fracture risk.
Which of the following drugs is contraindicated in heart failure?
A. Captopril
B. Celecoxib
C. Furosemide
D. Amiodarone
Explanation:
Celecoxib is a selective COX-2 inhibitor (NSAID). NSAIDs, including celecoxib, are contraindicated or strongly advised against in patients with heart failure (particularly mild to severe HF / NYHA class II–IV).
Reasons:
★Cause sodium and water retention → fluid overload and worsening of heart failure.
★Can increase blood pressure and reduce the effectiveness of diuretics, ACE inhibitors, and other heart-failure therapies.
★Associated with higher rates of HF hospitalization and adverse cardiovascular outcomes.
Comparison with the other options:
Among the listed options, only celecoxib is contraindicated in heart failure.
Exam Pearl:
Avoid NSAIDs, including COX-2 inhibitors, in patients with heart failure whenever possible because they may worsen fluid retention and precipitate decompensation.
Disclaimer: This educational content is intended for pharmacy students, healthcare professionals, and candidates preparing for NAPLEX, DHA, MOH, HAAD, SPLE, PEBC, and other pharmacy licensing examinations. The MCQs and explanations are provided for educational and exam-preparation purposes only and should not replace professional medical advice, clinical judgment, or official treatment guidelines. Medication selection and management should be based on current evidence, individual patient characteristics, and applicable clinical guidelines. Always consult a qualified healthcare professional before making decisions regarding patient care. Verify answers against authoritative references and current guidelines, as recommendations may change over time.
0 Comments